![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 34, 24100-24112, August 20, 1999
From the Inducible nitric-oxide synthase (iNOS) is a
hemeprotein that requires tetrahydrobiopterin (H4B) for activity. The
influence of H4B on iNOS structure-function is complex, and its exact
role in nitric oxide (NO) synthesis is unknown. Crystal structures of
the mouse iNOS oxygenase domain (iNOSox) revealed a unique H4B-binding
site with a high degree of aromatic character located in the dimer
interface and near the heme. Four conserved residues (Arg-375, Trp-455,
Trp-457, and Phe-470) engage in hydrogen bonding or
aromatic stacking interactions with the H4B ring. We utilized point
mutagenesis to investigate how each residue modulates H4B function. All
mutants contained heme ligated to Cys-194 indicating no deleterious
effect on general protein structure. Ala mutants were monomers except
for W457A and did not form a homodimer with excess H4B and Arg.
However, they did form heterodimers when paired with a full-length iNOS
subunit, and these were either fully or partially active regarding NO
synthesis, indicating that preserving residue identities or aromatic
character is not essential for H4B binding or activity. Aromatic
substitution at Trp-455 or Trp-457 generated monomers that could
dimerize with H4B and Arg. These mutants bound Arg and H4B with near
normal affinity, but Arg could not displace heme-bound imidazole, and
they had NO synthesis activities lower than wild-type in both
homodimeric and heterodimeric settings. Aromatic substitution at
Phe-470 had no significant effects. Together, our work shows how
hydrogen bonding and aromatic stacking interactions of Arg-375,
Trp-457, Trp-455, and Phe-470 influence iNOSox dimeric structure, heme
environment, and NO synthesis and thus help modulate the multiple
effects of H4B.
Nitric oxide (NO)1 is
produced by many cells and plays important roles in the nervous,
muscular, cardiovascular, and immune systems (1-5). Neuronal NOS
(nNOS, NOS 1) and endothelial NOS (eNOS, NOS 3) produce low NO
concentrations for neurotransmission, insulin release, penile erection,
vasorelaxation, oxygen detection, and memory storage, whereas
cytokine-inducible NOS (iNOS, NOS 2) produces larger NO concentrations
to counter pathogens and coordinate the immune response. The iNOS binds
calmodulin (CaM) very tightly and is not regulated by changes in
intracellular Ca2+, whereas the eNOS and nNOS isoforms both
bind CaM reversibly and are regulated by intracellular Ca2+
(6-8).
All three NOS exhibit a similar catalytic profile and composition. They
catalyze a two-step oxidation of L-arginine (Arg) to form
NO and citrulline, with N-hydroxy-L-arginine
(NOHA) being formed as an enzyme-bound intermediate (9-11). The
amino-terminal portion of each NOS represents an oxygenase domain
(amino acids 1-498 in mouse iNOS) that binds Fe-protoporphyrin IX
(heme), Arg, and (6R)-tetrahydrobiopterin (H4B) (12, 13).
The carboxyl-terminal portion of NOS represents a reductase domain
(amino acids 533-1172 in mouse iNOS) that contains binding sites for
NADPH, FAD, and FMN and bears much resemblance to cytochrome P450
reductase and other homologous dual flavin enzymes (9, 11, 13). An
intervening CaM-binding sequence (amino acids 503-532 for mouse iNOS)
separates the two domains. Each domain has distinct roles in catalysis
and in forming the active dimeric structure (12). For example, the iNOS
reductase domains, which do not appear to participate in the dimeric
interaction, transfer NADPH-derived electrons to the heme irons in the
oxygenase domain dimer, which enables the hemes to bind and activate
O2 during NO synthesis (9, 11-13).
The NOS oxygenase and reductase domains can be expressed separately and
fold and function independently of one another. This has facilitated
spectroscopic, kinetic, mutagenic, and crystallographic analysis of the
mouse iNOS oxygenase domain (iNOSox) (14-19). Mouse iNOSox that is
overexpressed in bacteria is primarily dimeric as purified and can bind
Arg and H4B with normal affinity. Moreover, iNOSox can synthesize NO
from the reaction intermediate NOHA when reducing equivalents are
provided by either free reductase domains (20) or
dithionite2 and also can
synthesize nitrite from NOHA in a
H2O2-supported reaction (17, 21). Both
full-length iNOS and iNOSox dimers can reversibly dissociate into
folded, heme-containing monomers in the presence of urea (12). These
full-length and iNOSox monomers recombine with one another when H4B and
Arg are present to form stable iNOS heterodimers (22). Because such
heterodimers contain only one reductase domain, they have been useful
in dissecting the electron transfer pathway in iNOS. For example, iNOS
heterodimers containing an Arg-binding mutation were used to show that
flavin-to-heme electron transfer in an iNOS dimer occurs exclusively
between reductase and oxygenase domains of adjacent subunits (23).
Besides providing one reason why dimerization is critical for NO
synthesis, this work also showed how heterodimers can help investigate
whether single mutations affect iNOS structure-function in a dimeric setting.
Determining how H4B functions in NOS catalysis is key to
understanding the enzyme reaction mechanism. Recently solved crystal structures for iNOSox and the eNOS oxygenase domain dimers (19, 24)
show that H4B is positioned perpendicular to the heme plane and at such
a distance from bound substrate that it cannot participate directly in
oxygen activation reactions critical for NO synthesis. This is
consistent with a variety of biochemical and kinetic evidence that
indicates H4B has important structural and electronic effects in iNOS.
For example, H4B promotes dimer assembly of iNOS heme-containing monomers (25), protects against proteolysis at Lys-117 in the amino-terminal hook (17), slows CO binding by 100-fold (14), prevents
binding of bulky ligands such as DTT (17) or nitrosoalkanes (26) to the
heme, and increases Arg binding affinity (27). Electronic effects
include H4B causing a high spin shift of the heme iron (21, 27-28),
increasing the heme midpoint potential (29), stabilizing the Fe-S bond
in ferrous-CO or -NO complexes (14, 30), and increasing the reactivity
of the ferrous-O2 complex
70-fold.3 Many of these
effects have also been observed in nNOS or eNOS. In particular, H4B
helps stabilize the nNOS dimer (31), increases the reactivity of its
ferrous-O2 complex (32), and has been suggested to act as
an electron donor under certain circumstances during NO synthesis (33).
However, there also appear to be differences among the NOS particularly
regarding a role for H4B in promoting dimer formation (24, 34).
Recent work has examined how various structural components of H4B and
its ring redox state help promote the H4B-induced effects noted above
and support NO synthesis. Studies utilizing tetrahydro- and
dihydropterin analogs of H4B show that whereas both the dihydroxypropyl side chain and the pterin ring help determine binding affinity toward
NOS, the side chain is more important than the ring in this regard (27,
35). Considering the pterin ring oxidation state, work with iNOS shows
that dihydrobiopterin can mimic H4B in promoting all of the structural
or electronic effects listed above except for increasing the reactivity
of the ferrous-O2 complex and supporting NO synthesis. This
suggests an essential role for H4B is to modulate reactivity of heme
iron-oxygen complexes during NO synthesis (32). In any case, protein
interactions with H4B are likely to modulate many of its electronic and
structural functions noted above.
From the iNOSox crystal structure it is clear that residues from both
the amino and carboxyl termini interact with H4B (19). Amino-terminal
residues interact primarily with the dihydroxypropyl side chain of H4B,
whereas residues in the carboxyl terminus primarily interact with the
pterin ring. Four highly conserved residues that interact with the
pterin ring are located in the substrate-binding helix (Arg-375) and in
a helical lariat structure (Trp-455, Trp-457, and Phe-470) (Fig.
1, A and B). Each
H4B interacts with two residues provided by the same subunit and two
provided by the adjacent subunit of the dimer, and contact with the H4B
ring occurs through Materials--
(6R)-H4B was purchased from Dr. B. Schirck's laboratory (Jona, Switzerland). Protein Expression and Purification--
Bacterial expression
and purification of the G450A full-length iNOS mutant (18) was done as
reported previously for wild-type full-length iNOS (36). Wild-type and
mutant iNOSox proteins (amino acids 1-498) with a His6 tag
attached to their carboxyl terminus were overexpressed in
Escherichia coli strain BL21(DE3) using a modified pCWori
vector (16). The cultures were grown with shaking at 250 rpm at
25 °C. Expression of protein was induced by adding 1 mM
isopropyl- Molecular Biology--
Restriction digestions, cloning,
bacterial growth, transformation, and isolation of DNA fragments were
performed using standard procedures (37). Site-directed mutagenesis was
done using the Altered Sites II in vitro Mutagenesis kit
from Promega. Mutant cDNAs were cloned into the NdeI and
SalI sites of the pCWori vector and transformed into
E. coli BL21(DE3) for protein expression.
UV-visible Spectroscopy--
Spectral data were recorded on a
Hitachi U3110 spectrophotometer in the presence or absence of H4B and
Arg. Scans of dithionite-reduced CO-bound proteins were taken in 40 mM EPPS, pH 7.6, containing 10% glycerol, 1 mM
DTT, 3 mM Arg, and various concentrations of H4B. The
ferrous-CO adduct absorbing at 444 nm was used to quantitate the
hemeprotein content using an extinction coefficient of 74 mM
Arg binding affinity was studied by perturbation difference
spectroscopy according to methods described previously (39, 40).
Protein samples were incubated with H4B overnight at 4 °C and then
diluted to ~3 µM in buffer containing 10% glycerol, 1 mM DTT, 300 µM H4B, and 0.4 mM
imidazole to promote formation of a low spin heme-imidazole complex
prior to titration. Spectra were recorded after equilibrium was reached
~10 min after each addition of Arg. The final sample volume change
was less than 5%. Difference spectra were generated by subtracting the
spectrum obtained without Arg from each subsequent spectrum using
Spectra Calc software (Galactic Industries Corp.). Apparent binding
constants for Arg were determined from double-reciprocal plots of the
difference in the respective peak to trough absorbances
versus the Arg concentration. For mutants whose Arg binding
affinity was determined in the presence of imidazole, we also
determined their imidazole binding affinities by serially adding
imidazole to a cuvette containing a mutant iNOSox, 0.5 mM
H4B, but no Arg, and a spectrum was recorded after each addition. The
data were analyzed by double-reciprocal plotting as described above to
determine imidazole Ks values. Imidazole
Ks values were then used in Equation 1 to correct for the effect of imidazole on the apparent Arg Ks
values (50),
Gel Filtration Analysis--
Dimer and monomer content of iNOSox
proteins was estimated by chromatography on an Amersham Pharmacia
Biotech Superdex-200 HR size-exclusion column equilibrated with 40 mM EPPS, pH 7.4, containing 10% glycerol, 0.25 M NaCl, and 0.5 mM DTT. The molecular weight of
the protein peaks were estimated relative to protein molecular weight
standards as described previously (17, 40).
Product Formation from NOHA--
Catalysis of nitrite production
from NOHA and H2O2 by iNOSox or mutants was
assayed in 96-well microplates at 37 °C as described previously (16,
41) with modifications. Assays (0.1 ml final volume) contained 100 mM EPPS, pH 7.5, 150 nM iNOSox hemeprotein, 1 mM NOHA, 0.5 mM DTT, 30 mM
H2O2, 10 units/ml superoxide dismutase, 50 µg/ml BSA, and variable concentrations of H4B (0.3-100
µM). Reactions were started by adding
H2O2 and stopped by adding catalase (1300 units). Griess reagent (0.1 ml) was then added, and the assay plate was
read at 550 nm in a Thermomax plate reader. Nitrite production was
quantitated based on NaNO2 standards.
Heterodimer Formation between iNOSox and Full-length G450A
iNOS--
For monomer formation, wild-type iNOSox or mutant iNOSox
proteins were incubated 1.5 h at a concentration of 50-70
µM in 40 mM EPPS pH 7.6, containing 5 M urea, 3 mM DTT, and 10% glycerol at
37 °C. They were then placed on ice and incubated for an additional 30 min. The samples were then diluted 10-fold with 40 mM
EPPS, 10% glycerol, and 3 mM DTT and incubated at various
concentrations (0-2.5 µM) with 200 nM
full-length G450A monomer for complementation experiments. Antagonist
experiments were done the same way except they also included 300 nM wild-type iNOSox monomer in each well. To promote
dimerization 1 mM BH4 and 20 mM Arg
were added to the protein mixtures to give a final volume of 50 µl,
and the samples were incubated for 1 h at 30 °C. For antagonist
experiments, protein mixtures were preincubated for 30 min prior to
adding H4B and Arg. After this dimerization incubation, heterodimer NO
synthesis was assayed by diluting each sample to 100 µl with assay
buffer such that each well contained a final concentration of 40 mM EPPS, 3 mM DTT, 4 µM FAD, 4 µM FMN, 800 µM H4B, 15 mM Arg,
1 mg/ml BSA, 18 units/ml catalase, and 10 units/ml superoxide
dismutase. NADPH (1 mM) was added to start the NO synthesis
reaction. The assays ran for 1 h at 37 °C, and the reactions
stopped by enzymatic oxidation of NADPH. Griess reagent (0.1 ml) was
added to each well, and the absorbance was measured at 550-650 nm in a
microplate reader. Absorbance due to nitrite produced in the reaction
was quantitated based on NaNO2 standards.
In some cases heterodimer NO synthesis was assayed using the
spectrophotometric oxyhemoglobin assay (23, 35). After the dimerization
incubation, sample aliquots were transferred from the microwells into
cuvettes containing 40 mM EPPS, pH 7.6, 10 mM
Arg, 0.1 mM H4B, 0.3 mM DTT, 1 mg/ml BSA, 10 units/ml superoxide dismutase, 100 units/ml catalase, 4 µM FAD and FMN, 5 µM oxyhemoglobin, and 300 µM NADPH in a total reaction volume of 500 µl.
Heterodimer concentrations ranged from 10 to 30 nM in the
cuvette, and the reactions were started by adding NADPH and run at
37 °C. The NO-mediated conversion of oxyhemoglobin to methemoglobin
over the first 5 min of the reaction was monitored at 401 nm and
converted to a rate of NO synthesis using the difference extinction
coefficient of All nine mutant iNOSox proteins were purified in the absence of
Arg and H4B. The amount of recoverable protein varied from 5 to 15 mg/liter culture, and all purified proteins displayed a normal heme
content and molecular mass (data not shown). Their dithionite-reduced,
CO-bound forms all displayed a Soret peak at 444 nm, indicating that
the heme iron in each mutant is ligated to Cys-194 as in wild-type
iNOSox (17). Gel filtration analysis revealed that seven mutants were
mostly or completely monomeric as purified (R375A, F470A, F470Y, W455A,
W455F, W455Y, and W457F), whereas two mutants (W457A and F470W) were
primarily dimeric (Table I), as is
typically observed for wild-type iNOSox purified under identical
conditions (17). Overnight incubation of monomer mutants with different
concentrations of H4B or with H4B plus Arg converted them to dimers in
most but not all cases (Fig. 2,
summarized in Table I). In particular, R375A, F470A, and W455A did not
dimerize even after overnight incubation with 1 mM H4B and
20 mM Arg. H4B alone (0.5 or 1 mM) promoted
dimerization of W455F, W455Y, W457F, and F470Y monomers, whereas Arg
alone (20 mM) promoted dimerization of wild-type iNOSox and
the mutant monomers F470Y, W455Y, W457A, and W457F but not W455F. Of
those mutants that could dimerize, maximum dimerization was typically
achieved in the presence of both Arg and H4B. These results indicate
that mutation of Arg-375, Phe-470, or Trp-455 to Ala prevented iNOSox
from forming a homodimer under any circumstance, whereas mutation of
Trp-457 to Ala, or mutations that preserved the aromatic character of
Phe-470, Trp-455, and Trp-457, did not prevent homodimer formation in
response to H4B and Arg.
All mutant proteins bound DTT to form a ferric bisthiolate complex with
characteristic split Soret band at 380 and 460 nm (data not shown), as
occurs for wild-type iNOSox dimer in the absence of Arg and H4B (17).
When BME replaced DTT as the buffer thiol, the mutants all displayed a
Soret absorbance at 415 nm indicating low spin ferric heme iron, as
occurs for wild-type iNOSox under these conditions (17). In general,
mutants that were dimeric as isolated, or mutant monomers that could
form a dimer in response to incubation with H4B and 20 mM
Arg, displayed spectral shifts in their Soret bands toward high spin
when incubated overnight with H4B plus Arg (Fig. 3,
A-D), as observed for
wild-type iNOSox (17). Incubation of these mutants with H4B or Arg
alone caused variable conversion to high spin (Fig. 3). For mutants that were monomeric as isolated, the spectral changes obtained correlated with the amount of dimerization achieved under each incubation condition. Mutants that could not dimerize in response to
Arg alone (W455F) or in response to H4B plus Arg (R375A, F470A, and
W455A) showed no spectral change after overnight incubation with Arg
and H4B, consistent with iNOSox monomer being unable to bind these
molecules (22, 25). These spectral results suggest that all mutant
homodimers underwent relatively normal changes in their heme iron
ligand environment upon binding H4B and Arg.
Mutational Analysis of the Tetrahydrobiopterin-binding Site in
Inducible Nitric-oxide Synthase*
,
,
,
Department of Immunology, Lerner Research
Institute, Cleveland Clinic, Cleveland, Ohio 44195, § Department of Molecular Biology, The Skaggs Institute for
Chemical Biology, Scripps Research Institute,
La Jolla, California 92037, and the ¶ Department of
Biochemistry, Chung-Ang Medical School, Seoul 156-756, Korea
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-stacking and/or hydrogen-bonding interactions
(Fig. 1, A and C). Together, these four residues
hold the pterin ring perpendicular to the heme plane and close enough
to directly hydrogen-bond to a heme propionate through pterin N-3 (19)
(Fig. 1C). To understand the importance of these four
residues (Arg-375, Trp-455, Trp-457, and Phe-470), we employed point
mutagenesis to ablate or modify their interactions with the H4B ring,
and we characterized each mutant regarding dimer formation, H4B and Arg
binding, and enzyme catalysis. We tested the effect of each mutant when
it was present in both subunits of an iNOSox homodimer and also when it
was present in only one subunit of a iNOS heterodimer comprised of an
oxygenase and full-length subunit. Our results show these four residues modulate H4B function in several ways and are important determinants for controlling iNOS structure-function.

View larger version (40K):
[in a new window]
Fig. 1.
Interaction of Arg-375, Trp-455, Trp-457, and
Phe-470 with H4B in an iNOSox dimer. A depicts a
yellow H4B molecule bound within the dimer interface. The
purple ribbon structure is from the same subunit to which
H4B is bound and represents residues 370-480 depicting the
substrate-binding helix (providing green Arg-375),
intervening helical T, and helical lariat (providing green
Trp-457) (19). A blue Arg molecule is also shown bound to
the substrate-binding helix and positioned above the
red heme group contained in this subunit of the dimer. The
gray ribbon structure is from the partner subunit and
represents residues 450-475 depicting the helical lariat (providing
orange Phe-470 and Trp-455). B aligns 10 NOS
polypeptide sequences from diverse life forms that contain the four
H4B-interacting residues, which are underlined. The
upper line illustrates the secondary structural elements
contained within the linear sequences. C illustrates
hydrogen-bonding interactions (dashed lines) between H4B and
Arg-375, Trp-457, Phe-470, and water molecules (W). Peptide
backbone carbonyl hydrogen-bonding interactions are depicted using a
carbonyl stick structure. A hydrogen-bonding interaction between H4B
and a heme propionate group is also shown.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Aminolevulinic acid,
Arg, bovine serum albumin (BSA), L-citrulline,
4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS), imidazole,
sodium dithionite, sodium nitrite, superoxide dismutase, catalase,
hydrogen peroxide were purchased from Sigma. Ampicillin and
isopropyl-
-D-thiogalactopyranoside were purchased from
Roche Molecular Biochemicals GmbH (Germany). NOHA was purchased from Alexis (San Diego, CA). DTT was purchased from Aldrich. Glycerol and Terrific Broth were purchased from Life Technologies, Inc. His-Bind
(nitrilotriacetate) resin was purchased from Novagen (Madison,
WI). Site-specific oligonucleotide-directed mutagenesis was
performed using the Altered Sites II in vitro mutagenesis system of Promega Biochemicals. Primers were synthesized by Life Technologies, Inc.
-D-thiogalactopyranoside to the culture when
it reached an optical density of 1 at 600 nm, and
-aminolevulinic acid was also added at this point to give a final concentration of 450 µM. Cells were harvested 48 h after induction by
centrifugation at 3600 rpm for 15 min. The cells from 4 liters of
culture were suspended in a minimum volume of lysis buffer containing
40 mM EPPS, pH 7.6, 0.5 mg/ml lysozyme, 10% glycerol, 0.5 µg/ml each of leupeptin, pepstatin, and phenylmethylsulfonyl
fluoride, 1 mM Arg, and 0.25 M NaCl. Cells were
broken by sonication (three 10-s pulses) followed by three cycles of
freezing and thawing in liquid N2 and at 37 °C,
respectively. The suspension was centrifuged at 13,200 rpm for 25 min
to remove cell debris, and the cytochrome P450 concentration of the
supernatant was checked. The crude extract was loaded onto a
Ni-nitrilotriacetate-Sepharose 4B column (2.5/10 cm) previously charged
with 50 mM NiSO4 and equilibrated with 40 mM EPPS buffer, pH 7.6, containing 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 0.25 M
NaCl (buffer A). The column was then washed with 10-bed volumes of
buffer A and 5-bed volumes of buffer A containing 40 mM
imidazole. Bound protein was eluted with buffer A containing 150-200
mM imidazole. Column fractions containing iNOSox were
pooled and concentrated using a Centriprep-30 (Millipore). The
concentrated proteins were dialyzed at 4 °C against two 500-ml volumes of 40 mM EPPS, pH 7.6, 10% glycerol, and 1 mM DTT and stored in aliquots at
70 °C.
1 cm
1
(A444-A500) (38).
Spectral analysis of H4B binding was done at room temperature using
protein samples that had been incubated overnight at 4 °C with
various concentrations of H4B (0.1-1 mM). Proteins were
diluted in 40 mM EPPS, pH 7.6, containing 5% glycerol and
3 mM DTT or 3 mM
-mercaptoethanol (BME) plus
different concentrations of H4B.
Arg binding for some mutants was studied without imidazole. In
this case proteins were incubated overnight at 4 °C with 1 mM H4B and then diluted in the same buffer as above
containing 1 mM H4B, and the spectra were recorded after
each addition of Arg and analyzed by double-reciprocal analysis.
(Eq. 1)
401 = 38 mM
1
cm
1.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Properties of iNOSox mutants

View larger version (32K):
[in a new window]
Fig. 2.
Effect of H4B or Arg on monomer-dimer
equilibrium of select iNOSox mutants. Gel filtration profiles were
obtained for mutants in the absence of H4B and Arg or after incubating
the mutants overnight at 4 °C with various concentrations of H4B and
Arg. A and D contain profiles of R375A and W457A
iNOSox mutants, respectively, in the absence of H4B and Arg
(1) or after incubation with 1 mM H4B plus 20 mM Arg (2). B and C
contain profiles of W455F and W455Y iNOSox mutants, respectively, in
the absence of H4B and Arg (1), or after incubating
overnight with 0.5 mM H4B (2), 1 mM
H4B (3), 20 mM Arg (5), or 1 mM H4B plus 20 mM Arg (4). Dimer
(D) and monomer (M) peaks are indicated by
arrows and were identified based on retention times for
protein molecular weight standards and wild-type iNOSox.

View larger version (28K):
[in a new window]
Fig. 3.
Light absorbance spectra of select iNOSox
mutants. Spectra were recorded for mutant proteins after dilution
in buffer containing 3 mM BME alone (-Arg, -H4B)
or after incubating the mutant proteins overnight at 4 °C in buffer
containing BME plus various combinations of Arg or H4B as indicated.
Spectra were recorded at 15 °C.
Arg binding affinities of iNOSox mutant homodimers were quantitated by spectral perturbation assay (17, 39). Spectral change versus increasing Arg concentration was recorded in the presence or absence of 0.4 mM imidazole and H4B. In all cases, protein samples were preincubated overnight with 0.5 or 1 mM H4B, and these H4B concentrations were maintained after diluting the enzyme for Arg titration. The spectral change observed for each mutant upon addition of 0.4 mM imidazole indicated its binding to the heme iron was complete at this concentration. To aid in comparing apparent Ks values for Arg, imidazole titrations were performed on select proteins and gave estimated imidazole Ks values of 56 µM for wild-type iNOSox and 50, 31, and 23 µM for F470Y, F470W, and W457F mutants, respectively.
Upon sequential addition of Arg, we obtained spectral changes that
indicated a complete displacement of imidazole only for wild-type
iNOSox and the F470Y and F470W mutants (F470W is shown in
Fig. 4). The apparent Arg
Ks values for these two mutants in the presence of
0.4 mM imidazole were derived by double-reciprocal analysis
and were 26 and 50 µM, respectively, as compared with 25 µM for wild-type iNOSox under the same conditions (Table
I). When each protein's different imidazole affinity is taken into account, corrected Arg Ks values for the F470Y and
F470W mutants were 2.9 and 3.6 µM, respectively, similar
to the corrected Arg Ks for wild-type iNOSox (3.1 µM).
|
Other mutant homodimers either achieved an incomplete displacement of imidazole at Arg saturation (W457F, Fig. 4), or exhibited no displacement of imidazole (W455Y, W455F, and W457A) even at Arg concentrations up to 50 mM (data not shown). In these cases, Arg spectral perturbation was measured in the absence of imidazole. W455F, W455Y, and W457F completely converted to high spin during Arg titration in the absence of imidazole and had estimated Ks values between 80 and 150 µM (W455Y titration is shown in Fig. 4, all Ks values are in Table I). The W457A mutant dimer was unstable over the course of the Arg titration, and consequently its Ks value could not be determined.4 Together, our results indicate that Arg can bind to all mutant homodimers, and their effect on Arg affinity ranges from none to a decrease by less than a factor of 10.
We next examined the ability of each mutant homodimer to catalyze
nitrite formation from NOHA in a 10-min
H2O2-supported reaction (16). This assay
directly measures activity of oxygenase domain homodimers because it
does not require electron donation from an iNOS reductase domain. Each
concentrated wild-type and mutant iNOSox (20-80 µM) was
incubated overnight with 1 mM H4B. The next day the
dimer-monomer ratio of each sample was determined by gel filtration
(see Table I), and the proteins were diluted to 150 nM in
the wells and assayed immediately in the presence of 1 mM NOHA and increasing H4B concentrations. H4B carryover from the overnight incubations ranged from 2 to 8 µM. As shown in
Fig. 5, all mutants except W457A showed
increasing activity as the H4B concentration increased. Table I
contains the estimated H4B EC50 values derived from this
experiment which ranged from 3 to 16 µM, as compared with
an EC50 value for wild-type iNOSox of 1.3 µM
derived from the same assay.
|
Because the activity of the W457A mutant did not increase with
increasing H4B concentration, we used spectroscopy to check if H4B and
NOHA bound to W457A under the conditions of the
H2O2 assay. As shown in Fig.
6, adding 0.1 mM H4B plus 1 mM NOHA completely displaced DTT from the W457A heme iron,
indicating saturation of their binding sites was achieved under the
assay conditions.
|
Mutant proteins incubated overnight with 1 mM H4B achieved only partial dimerization in most cases (see Table I). Therefore, activities of the mutants as illustrated in Fig. 5 could not be compared directly without first normalizing for dimer content. When their different dimerization is taken into account (see Table I), the W457A mutant homodimer had the lowest activity compared with wild-type iNOSox, mutant dimers F470W, W455Y, and W455F had activities that ranged from 51 to 66% of wild-type, and mutant dimers F470Y and W457F had activities equivalent to wild-type in the H2O2-driven NOHA oxidation assay.
We next examined how each mutation would affect catalytic function when
it was present in only one oxygenase domain subunit of an iNOS
heterodimer. Our previous work (22, 23) had shown that in a heterodimer
comprised of one full-length and one oxygenase domain subunit, the
single reductase domain transfers electrons only to the adjacent
oxygenase domain partner, and this intersubunit electron transfer
supports a full rate of NO synthesis by that oxygenase domain. To make
heterodimers using our mutant iNOSox proteins, they were converted to
monomers by dissociation in urea, diluted, and incubated with
full-length iNOS monomer under conditions that induce dimerization (H4B
plus Arg), and finally assayed for NO synthesis in a subsequent 60-min
reaction. In this system we used a full-length iNOS monomer containing
a point mutation (G450A) that prevents it from forming a homodimer with
itself but allows it to form an active homodimer with either wild-type
iNOSox monomer or with iNOSox monomers that contain mutations distinct
from G450A (18, 42). Thus, we studied the ability of each iNOSox point mutant to "complement" the G450A iNOS monomer regarding heterodimer formation and NO synthesis. We also tested the ability of each mutant
to compete with or "antagonize" wild-type iNOSox monomer in forming
a heterodimer with G450A iNOS, as a measure of the mutants affinity
toward the G450A subunit. The complementation and antagonism
experimental methods are illustrated in
Fig. 7.
|
Fig. 8A shows results obtained
in G450A complementation studies using wild-type iNOSox, three Phe-470
mutants (Tyr, Trp, and Ala), and the R375A mutant. When increasing
quantities of wild-type iNOSox monomer were incubated with a constant
amount of full-length G450A under dimerization conditions, we observed
a dose-dependent increase in NO synthesis activity that
approached saturation at higher iNOSox to G450A subunit ratios. This
indicated heterodimer formation had occurred. The maximal specific
activity achieved (477 nmol of NO per min per mg of Gly-450
hemeprotein), as measured by the oxyhemoglobin assay, is similar to the
activity of an iNOS heterodimer comprised of wild-type full-length and
oxygenase iNOS subunits assayed under similar conditions (~400 nmol
NO per min per mg) (22). This indicates that all of the G450A subunits in the reaction formed a heterodimer when excess iNOSox monomers were
present and that this heterodimer has normal activity. Experiments utilizing F470Y or F470W iNOSox monomers in place of wild-type iNOSox
gave activity versus concentration curves almost identical to wild-type iNOSox (Fig. 8A). Thus, these two mutations do
not affect NADPH-dependent NO synthesis by the heterodimer.
In contrast, the F470A and R375A iNOSox monomers achieved maximum
heterodimer NO synthesis activities that were 40 and 25% the activity
obtained with wild-type iNOSox, respectively. This suggests that the
F470A or R375A mutations impact negatively on NO synthesis when they are present in the active oxygenase subunit of the heterodimer.
|
We also examined the ability of the F470Y, F470A, and R375A mutant iNOSox monomers to compete with a fixed amount of wild-type iNOSox in forming a heterodimer with G450A (Fig. 8B). This antagonism study showed that increasing concentrations of F470Y iNOSox did not affect the NO synthesis activity of the system, consistent with the F470Y mutant forming a heterodimer whose activity is equivalent to a heterodimer formed with wild-type iNOSox (see Fig. 8A). In contrast, adding increasing amounts of the F470A or R375A monomers in the antagonism study lowered heterodimer NO synthesis activity in a concentration-dependent manner down to levels that were equivalent to the maximum activities obtained for each mutant's complementation assay in Fig. 8A. Thus, excess F470A and R375A monomers could compete successfully and completely with wild-type iNOSox monomer in forming a heterodimer with the G450A subunit. This indicated a good affinity toward the G450A subunit and confirmed that heterodimers containing a F470A or R375A subunit possess a lower activity than wild type.
Similar G450A complementation and antagonism experiments were performed with the W457F or W457A monomers (Fig. 8, C and D) and with the W455A, W455Y, or W455F monomers (Fig. 8, E and F). Heterodimers containing a W457F or W457A iNOSox subunits were only 12 or 28% as active as a heterodimer containing wild-type iNOSox, whereas heterodimers containing W455Y or W455F iNOSox subunits were 70 and 45% as active as wild type, respectively. All mutants except W455A were also complete antagonists. Thus they have good affinity toward the G450A monomer, and their maximal activities accurately reflect how each mutation affects heterodimer NO synthesis Vmax. In contrast, the poor ability of the W455A monomer to antagonize heterodimer formation between G450A and wild-type iNOSox subunits suggests the low activity of the W455A heterodimer (Fig. 8E) is primarily due to a dimerization defect.
The relative maximal activities of the mutant heterodimers as shown in Fig. 8 were independently checked by assaying for NO synthesis using the oxyhemoglobin assay. Heterodimers were formed in reactions that contained a 10 to 1 ratio of iNOSox mutant monomer to G450A monomer. As shown in Table II, the NO synthesis activities of the heterodimers had a similar rank order to the activities as measured by the nitrite accumulation assay, confirming that certain mutations substantially decreased NO synthesis activity when present in the active subunit of an iNOS heterodimer.
|
| |
DISCUSSION |
|---|
|
|
|---|
NOSs are the only heme-containing enzymes known to require a pterin cofactor for activity. The influence of H4B on NOS structure and catalysis is complex and may differ among the NOS isoforms (4, 11, 12, 35). Here we utilized mutagenesis to investigate how four conserved residues that interact primarily with the H4B ring help modulate its function in iNOS.
Mutagenesis of these four residues produced a range of effects including destabilization of iNOSox homodimeric structure, reduced binding affinity toward H4B and substrate, changes in heme environment, and reduced rates of NO synthesis. However, no mutations destabilized heme incorporation or its proper ligation with Cys-194, despite several mutants being expressed as heme-containing monomers. This indicates that none of the point mutations perturbed iNOSox folding to form a monomer or its overall structure. Mutation results for each of the four residues is discussed in turn below, followed by a more general discussion.
Arg-375 is located on the substrate binding helix
7a (Fig.
1A), which participates in an extensive hydrogen bond
network involving charged residues of the
7 helix. It interacts with an H4B molecule bound within the same subunit exclusively through its
guanidine nitrogens, which hydrogen-bond directly to pterin O-4 and
indirectly to pterin N-5 via a water molecule (Fig. 1C). The
carboxylate of Asp-379, also found on
7a, hydrogen-bonds to the
Arg-375 guanidinium group and positions Arg-375 to serve as a book end
for the stacking of H4B with Trp-457. Thus, substitution of Arg-375 to
Ala will disrupt
-stacking, hydrogen bond interactions, and
electrostatic complementarity in the iNOS dimer.
Because Arg-375 is a central structural residue for the H4B-binding site, the active center, and the dimer interface, it is not surprising that R375A mutants are isolated primarily as monomers that do not form a homodimer in response to H4B or Arg. The minor amount of dimeric R375A that we observe is likely to have formed through H4B-independent dimerization, which occurs extensively for wild-type iNOS when it is expressed in bacteria (Table I). The inability of R375A to dimerize further in response to H4B or Arg implies that the mutation either prevents their binding to or stabilization of the mutant homodimer. In any case, the R375A monomer clearly formed a heterodimer with a full-length iNOS G450A subunit, which generated NO from Arg at ~25% of the wild-type activity. This shows the following: 1) the R375A subunit can bind H4B and Arg productively when coerced into a dimeric state; and 2) the multiple hydrogen-bonding interactions and positive charge supplied from Arg-375 cannot be absolutely essential for H4B binding or to support NO synthesis but may be needed to optimize binding affinity, dimerization, and catalysis by iNOS.
As noted by Raman et al. (24) ricin also recognizes pteridine-based inhibitors with an Arg residue that interacts with O-4 of the pterin ring (43), whereas in dihydropteroate synthase a positively charged Lys recognizes pterin rings at O-4 (44). Perhaps the closest analogy to iNOS Arg-375 occurs in dimethyl sulfoxide reductase, where an Arg is positioned in a conformation similar to iNOS Arg-375 and hydrogen-bonds to an O-4 equivalent on the molybdopterin cofactor (45, 46). However, the roles of pterin and overall structures of the binding sites are very different in all of these enzymes. This implies that hydrogen bonding between pterin O-4 and a positively charged residue does not confer specific chemical or electronic functionality on H4B but rather enables proper binding of the cofactor. Interestingly, mutation of the analogous Arg residue in human eNOS (R365L), which hydrogen-bonds to the O-4 of H4B as in iNOS, did not completely prevent eNOS homodimer formation as judged by the mutant possessing considerable citrulline synthesis activity (47). This suggests that differences exist among NOS isoforms regarding a role for this Arg residue in H4B binding and function.
The H4B-binding sites of iNOS and eNOS are distinguished by a high
degree of aromatic character primarily provided in iNOS by Trp-455,
Trp-457, Phe-470, and the H4B ring itself. Of these residues, Trp-457
is located on the helical lariat and interacts with an H4B that is
contained within the same subunit. The indole ring of Trp-457 is
involved in an extensive
-stacking arrangement that also includes
Phe-470 from the partner subunit (Fig.
9). The indole ring is sandwiched between
H4B's ring and the guanidinium of Arg-193, which is probably involved
in a favorable interaction with the quadrupole of the indole ring. One
end of the Trp-457 indole ring lies between the A and D pyrrole rings
of the heme, whereas the other is contacted by Met-114 (Fig. 9), which
is located in the amino-terminal H4B-binding segment (19). Trp-457 also forms hydrogen bonds between its
-carbonyl and the N-2 and N-1 nitrogens of the H4B ring (Fig. 1C). In addition, the indole NH hydrogen bonds to a water molecule that interacts with the terminal hydroxyl group of the chain of H4B.
|
The W457F mutant is predicted to conserve the aromatic stacking and
backbone hydrogen-bonding interactions with H4B, whereas the W457A
mutation should only conserve hydrogen-bonding between the ring
nitrogens of H4B and the peptide backbone. Surprisingly, substitution
of Trp-457 to Ala did not significantly destabilize the dimeric
structure in the as-isolated protein, whereas substitution to Phe did,
even though the W457F mutant still dimerized in the presence of H4B or
Arg. Both mutants readily formed heterodimers with a full-length G450A
subunit and acted as good antagonists. This indicates that
-stacking
of Trp-457 with H4B may have only a minor role in stabilizing the
dimeric structure and that it is more detrimental structurally to
replace Trp-457 with an aromatic of different size than to remove it
completely. However, maintaining the stacking interaction may be
critical for controlling heme environment and reactivity, as manifested
by the inability of Arg to displace heme-bound imidazole in the W457A
mutant and its lower rate of catalysis in both the
H2O2-driven NOHA oxidation and heterodimer NO
synthesis assays. Because our spectral results show that W457A was able
to fully bind H4B and substrate under the conditions of the catalytic
assay (see Fig. 6), we can conclude its diminished activities are not
related to poor binding of substrate and cofactor. Likewise, its low
activities cannot be explained by poor dimerization (see Table I).
Thus, Trp-457 must have an important direct role that helps H4B to
support NO synthesis. Possibilities to investigate include the effect
of H4B on heme iron reduction (35), heme iron-oxy reactivity (32), and
formation or stabilization of a heme-NO complex during steady-state NO
synthesis (48, 49).
W457F, which potentially preserves a stacking interaction with H4B, displayed relatively normal spectral properties although imidazole displacement by Arg was incomplete. This mutant's rate of NOHA oxidation in the H2O2-driven assay was normal, but it was only 30% as active as wild-type in the heterodimer NO synthesis assay. This suggests aromatic substitution at Trp-457 does not alter heme catalytic activity in the simpler assay system, but maintaining Trp at position 457 is important for NO synthesis from Arg, which is a much more complex reaction.
Each H4B-binding site in NOS is comprised of residues supplied from both subunits. In addition, several structural interactions occur between the helical lariats of the two subunits that couple the H4B-binding sites together within the dimer interface (19). Phe-470 and Trp-455, which are positioned on the helical lariat, contact the H4B molecule that is bound in the adjacent subunit. In the crystal structure Phe-470 and Trp-455 stack against the H4B ring on the side opposite to Trp-457, with the Phe-470 ring tilted to complement the tetrahydropyrazine ring pucker and (6R)-dihydroxypropyl side chain projection (see Figs. 1A and 9). The backbone carbonyl of Phe-470 hydrogen-bonds with H4B side chain hydroxyl O-9 and the phenyl ring also contacts Ser-465 and His-471 of the same subunit. In addition, Phe-470 buries ~55-A2 in the dimer interface by contacting Trp-455 and Pro-461 of the adjacent subunit. Phe-470 is further stabilized by a hydrogen bond between its peptide carbonyl and the indole nitrogen of Trp-455. Trp-455 itself contacts the H4B side chain and stabilizes conformations for Ile-456 and Val-459 of the adjacent subunit. This residue buries 70 A2 in the dimer interface, primarily by stacking with its own symmetry mate (Trp-455) on the adjacent subunit. Thus, in addition to their H4B contacts, Phe-470 and Trp-455 have multiple interactions with residues from both subunits and are integral components of the dimer interface.
Aromatic substitution mutations of Phe-470 and Trp-455 altered dimer stability and substrate- or H4B-protein interactions to various degrees but never completely prevented dimer formation, binding of H4B and substrate, or NO synthesis. Only substitution at Trp-455 altered the iNOS heme environment as judged by an inability of Arg to displace heme-bound imidazole. Aromatic substitution at Phe-470 had either a minor or no effect on catalysis as measured in the H2O2-driven NOHA oxidation or heterodimer NO synthesis assays, whereas aromatic substitution at Trp-455 decreased activity in both activity assays. Ala substitution at Phe-470 completely prevented homodimer formation, but this mutant still formed a heterodimer with a full-length G450A subunit which had significant NO synthesis activity. In contrast, Ala substitution at Trp-455 completely prevented homodimerization and almost completely prevented formation of the G450A heterodimer, in this way severely diminishing NO synthesis.
Together, our results suggest a proper stacking interaction between Phe-470 and H4B can be provided by other aromatic residues, and thus the precise interaction supplied by Phe-470 is not critical. In contrast, altering the stacking and protein hydrogen-bonding interactions of Trp-455 have a greater and broad effect on iNOS structure and catalysis that may involve both subunits of the iNOS dimer. Indeed, although it is clear that mutations of Phe-470 and Trp-455 should affect H4B binding or function in the opposite subunit, the extensive structural integration of the two H4B sites and participation of Trp-455 residues from both subunits in forming the dimer interface help explain why the W455F and W455Y heterodimers had lower rates of NO synthesis even when the mutations were located in the same subunit as the active heme.
Although Arg-375, Trp-455, Trp-457, and Phe-470 each appear important for H4B functions in iNOS, our results reveal that NO synthesis does not absolutely depend on preserving the individual identities of any of these four residues. Thus, none of their functional group interactions with H4B or with other protein residues are absolutely critical. It is important to note that this conclusion could only be reached by virtue of heterodimer experiments, which allowed us to determine how mutations that completely prevented iNOS homodimer formation (most Ala mutants) affect iNOS catalysis in a dimeric setting.
A body of evidence suggests that many mutations limit or prevent iNOS NO synthesis primarily by limiting homodimer formation. Known mutations that completely prevent iNOS homodimer formation (and consequent NO synthesis) include certain amino-terminal deletion mutants (17), point mutants G450A and A453I (42), and three of the four Ala mutants described in the present report. In principle, this mechanism of inhibition also applies for any mutant that has a partial dimeric structure under a given experimental setting because H4B or Arg concentrations were insufficient for full dimer formation (16, 17). Our work shows that provision of sufficient H4B and Arg, and heterodimer experiments, can often circumvent dimerization defects and thereby allow study of how a given mutation effects NO synthesis by the dimer itself.
Three mutations described in this report (W457A, W455F, and W455Y) altered the iNOS heme environment as judged by an inability of Arg to displace imidazole bound to the heme. Similar effects on heme environment have also been reported for eNOS point mutants (47). For our iNOS mutants, the inability of substrate to displace bound imidazole could not be explained by poor dimerization or lack of Arg or H4B binding. The defect may also be ligand-specific, because in these same mutants Arg could fully displace DTT bound to the heme iron.5 That mutations in the H4B-binding site can effect Arg-heme ligand interactions is consistent with the iNOS crystal structure that shows Arg binds directly over the heme and an extensive integration exists between the H4B and substrate-binding sites (19). However, because the changes in substrate-heme ligand interactions did not correlate well with loss of catalytic activity in the iNOS mutants, it is presently unclear how they relate to iNOS function.
Mutant activity as measured by the H2O2-driven
NOHA oxidation assay was usually affected to the same degree or in some
cases was less sensitive to a given mutation than was heterodimer NO synthesis. This has potentially important implications. As shown in
Fig. 10, the NOS heme is thought to
activate oxygen in a stepwise manner with formation of three distinct
iron-oxy species. Provision of H2O2 to ferric
NOS enables formation of heme iron-peroxy species II and potentially
formation of the iron-oxo species III and, therefore, bypasses electron
transfer and oxygen activation steps that normally occur during
NADPH-driven NO synthesis (21, 32, 33). Thus, observing normal activity
in the H2O2-driven assay implies that a given
mutation does not effect formation or reactivity of species II (or
potentially species III) toward NOHA. When such mutants display good
heterodimer formation but slow heterodimer NO synthesis from Arg, the
mutation must either slow the tempo of electron transfer to the heme,
alter formation or reactivity of the iron-oxy species toward Arg, or
stabilize the inactive heme-NO complex that forms during steady-state
NO synthesis. Such changes could explain why aromatic substitution
mutants W457F and W455F have slow heterodimer NO synthesis although the
-stacking and hydrogen-bonding interactions of the native residues
are largely preserved. Perhaps these facets of catalysis, which are
unique to NADPH-dependent NO synthesis from Arg, are more
sensitive to the precise positioning or environment provided by these
residues. Further work to understand these issues is underway in
our laboratories.
|
It has been proposed that H4B may participate in NOS heme reduction by serving as an intermediate in the electron transfer pathway between the flavins and heme iron (24, 33). Under this circumstance, the quadrupole moments of the aromatic residues surrounding the cofactor might help stabilize an H4B cation radical species formed during an electron transfer event (24, 33). Mutation of aromatic residues contacting H4B could then be envisioned to down-regulate NO synthesis by destabilizing a pterin cation radical and thus modulating the ability of H4B to accept or donate flavin-derived electrons to the heme. Although our data do not formally rule out this possibility, we believe it is unlikely because flavin-dependent heme iron reduction still occurs in both iNOS and nNOS6 in the absence of bound H4B (29, 35). Moreover, the rate of heme iron reduction in H4B-free iNOS is equal to or slightly faster than the rate in H4B-saturated iNOS (35). This at minimum shows that H4B is not required to achieve a normal rate of flavin-mediated heme iron reduction in NOS. Indeed, our previous data indicate that an essential role of H4B may be to modulate the reactivity of NOS heme iron-oxy complexes that form during NO synthesis (32). In addition, the heme edge in an iNOSox dimer is close to a surface that can interact directly with the reductase domain, whereas H4B is buried in the dimer interface (19) and could only obtain electrons from the reductase by an indirect transfer route.
Comparing all NOS primary sequences available in the data base reveals
that the four residues mutated in this report are almost completely
conserved across 26 NOS from a wide variety of life forms. The single
exception is Trp-457 which in the great pond snail is an Arg (see Fig.
1B). Such strict conservation contrasts with our data
showing some tolerance toward aromatic substitution with regard to NO
synthesis. What selective pressure has maintained residue identities
(beyond the fact that some aromatic substitutions would involve a
double mutation of the codon) is unclear. Our current data suggest that
dimer destabilization or some loss of H4B binding affinity caused by
mutation might help maintain selective pressure in vivo.
Studies that examine assembly and function of the H4B site mutants in
whole cells should shed light on this issue.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Pam Clark and Pam Mackowski for excellent technical support.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants CA53914 and HL58883.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Immunology NN-1,
Lerner Research Institute, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-6950; Fax: 216-444-9329; E-mail: stuehrd@cesmtp.ccf.org.
2 S. Boggs, L. Huang, H. Abu-Soud, and D. J. Stuehr, unpublished results.
3 H. Abu-Soud and D. J. Stuehr, unpublished results.
4 The protein was unstable at room temperature. However, it became fully high spin when incubated overnight with Arg and H4B at 4 °C (see Fig. 2D).
5 S. Ghosh and D. J. Stuehr, unpublished results.
6 In H4B-free iNOS, NADPH-dependent heme reduction requires that Arg or an Arg analog is bound, but this is not required in H4B-free nNOS (29, 35).
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
NO, nitric oxide;
NOS, NO synthase;
Arg, L-arginine;
H4B
(6R)-5,6,7,8-tetrahydro-L-biopterin, BME,
-mercaptoethanol;
CaM, calmodulin;
BSA, bovine serum albumin;
DTT, dithiothreitol;
EPPS, 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic
acid;
H2O2, hydrogen peroxide;
iNOS, mouse
macrophage inducible NO synthase;
iNOSox, oxygenase domain of iNOS;
NOHA, N
-hydroxy-L-arginine;
eNOS, endothelial NOS;
nNOS, neuronal NOS.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Gross, S. S., and Wolin, M. S. (1995) Annu. Rev. Physiol. 57, 737-769[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Dawson, T. M., and Dawson, V. L. (1996) Annu. Rev. Med. 47, 219-227[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Nathan, C. (1997) J. Clin. Invest. 100, 2417-2423[Medline] [Order article via Infotrieve] |
| 4. | Mayer, B., and Werner, E. R. (1995) Nauyn Schmiedeberg Arch. Pharmacol. 351, 453-458[Medline] [Order article via Infotrieve] |
| 5. | Michel, T., and Feron, O. (1997) J. Clin. Invest. 100, 2146-2152[Medline] [Order article via Infotrieve] |
| 6. |
Cho, H. J.,
Xie, Q. W.,
Calaycay, J.,
Mumford, R. A.,
Swiderek, K. M.,
Lee, T. D.,
and Nathan, C.
(1992)
J. Exp. Med.
176,
599-604 |
| 7. |
Garcia-Cardena, G.,
Martasek, P.,
Masters, B. S. S.,
Skidd, P. M.,
Couet, J.,
Li, S.,
Lisanti, M. P.,
and Sessa, W. C.
(1997)
J. Biol. Chem.
272,
25437-25440 |
| 8. |
Venema, R. C.,
Sayegh, H. S.,
Kent, J. D.,
and Harrison, D. G.
(1996)
J. Biol. Chem.
271,
6435-6440 |
| 9. | Griffith, O. W., and Stuehr, D. J. (1995) Annu. Rev. Physiol. 57, 707-736[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Marletta, M. A.
(1993)
J. Biol. Chem.
268,
12231-12234 |
| 11. | Mayer, B., and Hemmens, B. (1997) Trends Biochem. Sci. 22, 477-481[CrossRef][Medline] [Order article via Infotrieve] |